Medical update and potential advances in the treatment of pediatric intestinal failure

Current Gastroenterology Reports

Volumn 14, Issue 3, 2012, Pages 243-252

  Youssef, Nader N ^a,b,c   Mezoff, Adam G ^d,e   Carter, Beth A ^f,g   Cole, Conrad R ^d,e  

^a UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

^b NPS Pharmaceuticals   (United States)

^c Digestive HealthCare Center   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Texas Children's Pediatric Intestinal Rehabilitation Program   (United States)

Author keywords

Advances; Children; Infant; Intestinal failure; Intestinal rehabilitation; Management; Pediatric intestinal failure; Short bowel syndrome; Treatment

Indexed keywords

ALCOHOL; CITRULLINE; GLUCAGON LIKE PEPTIDE 2; GLUTAMINE; GROWTH HORMONE; HUMAN GROWTH HORMONE; OMEGAVEN; RECOMBINANT GROWTH HORMONE; TEDUGLUTIDE; URSODEOXYCHOLIC ACID;

BACTERIAL OVERGROWTH; CARBOHYDRATE DIET; CATHETER INFECTION; CHOLESTASIS; CLINICAL ASSESSMENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; ENERGY EXPENDITURE; ENTERIC FEEDING; FEEDING; HUMAN; INCIDENCE; INTESTINAL FAILURE; LIPID DIET; MACRONUTRIENT; NONHUMAN; NUTRITIONAL DEFICIENCY; PARENTERAL NUTRITION; PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS; PEDIATRICS; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DIET; REVIEW; RISK FACTOR; SHORT BOWEL SYNDROME;

BIOLOGICAL MARKERS; BLIND LOOP SYNDROME; CATHETER-RELATED INFECTIONS; CHILD; ENTERAL NUTRITION; GASTROINTESTINAL AGENTS; HUMANS; MALABSORPTION SYNDROMES; NUTRITION DISORDERS; PEPTIDES; SHORT BOWEL SYNDROME;

EID: 84861096711     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0262-8     Document Type: Review

References (67)

1. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4:6-10. (Pubitemid 43129518)
2. Fleming C, Remington M. Intestinal failure. In: Hill G, editor. Nutrition and the surgical patient. Edinburgh: Churchill Livingston; 1981. p. 219-35.
3. Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep. 2007;9:463-7. (Pubitemid 351795703)
4. Goulet O, Ruemmele F, Lacaille F, Colomb V. Irreversible intestinal failure. J Pediatr Gastroenterol Nutr. 2004;38:250-69.
5. Salvia G, Guarino A, Terrin G, Cascioli C, Paludetto R, Indrio F, Lega L, Fanaro S, Stronati M, Corvaglia L, Tagliabue P, De Curtis M. Neonatal onset intestinal failure: an Italian multicenter study. J Pediatr. 2008;153:674.e2-6.e2.
6. Wales PW, de Silva N, Kim J, Lecce L, To T, Moore A. Neonatal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg. 2004;39:690-5. (Pubitemid 38637917)
7. Koffeman GI, van Gemert WG, George EK, Veenendaal RA. Classification, epidemiology and aetiology. Best Pract Res Clin Gastroenterol. 2003;17:879-93.
8. Bakker H, Bozzetti F, Staun M, Leon-Sanz M, Hebuterne X, Pertkiewicz M, Shaffer J, Thul P. Home parenteral nutrition in adults: a European multicentre survey in 1997. ESPEN-Home Artificial Nutrition Working Group. Clin Nutr. 1999;18:135-40. (Pubitemid 29352027)
9. Guarino A, De Marco G. Natural history of intestinal failure, investigated through a national network-based approach. J Pediatr Gastroenterol Nutr. 2003;37:136-41. (Pubitemid 39274538)
10. Cole CR, Hansen NI, Higgins RD, Ziegler TR, Stoll BJ, for the Eunice Kennedy Shriver NNRN. Very low birth weight preterm infants with surgical short bowel syndrome: incidence, morbidity and mortality, and growth outcomes at 18 to 22 months. Pediatrics. 2008;122:e573-82.
11. Casey L, Lee KH, Rosychuk R, Turner J, Huynh HQ. 10-year review of pediatric intestinal failure: clinical factors associated with outcome. Nutr Clin Pract. 2008;23:436-42.
12. Pakarinen MP, Koivusalo AI, Rintala RJ. Outcomes of intestinal failure - a comparison between children with short bowel and dysmotile intestine. J Pediatr Surg. 2009;44:2139-44.
13. Feldman EJ, DowlingRH, McNaughton J, et al. Effects of oral versus intravenous nutrition on intestinal adaptation after small bowel resection in the dog. Gastroenterology. 1976;70(5 PT1):712-9.
14. Tyson J, Kennedy K. Minimal enteral feeding for promoting feeding tolerance and preventing morbidity in parenterally fed infants. Cochrane Database Syst Rev. 1997;4:CD000504.
15. Ekingen G, Ceran C, Guvenc BH, Tuzlaci A, Kahraman H. Early enteral feeding in newborn surgical patients. Nutrition. 2005;21:142-6. (Pubitemid 40255722)
16. Andorsky DJ, Lund DP, Lillehel CW, Jaksic T, Dicanzio J, Richardson D, Collier SB, Lo C, Duggan C. Nutritional and other post- operative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr. 2001;139:27-33. (Pubitemid 32613983)
17. Playford RJ, Macdonald CE, Johnson WS. Colostrum and milkderived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr. 2000;72:5-14. (Pubitemid 30441650)
18. Crenn P, Morin MC, Joly F, Penven S, Thuillier F, Messing B. Net digestive absorption and adaptativehyperphagia in adult short bowel patients. Gut. 2004;53:1279-86. (Pubitemid 39120113)
19. Lennard-Jones JE. Oral rehydration solutions in short bowel syndrome. Clin Ther. 1990;12(supp a):129-37.
20. Bhatia J, Gates A, Parish A. Medical management of short gut syndrome. J Perinatol. 2010;30:S2-5.
21. Jackson CS, Buchman AL. The nutrional management of short bowel syndrome. Nutr Clin Care. 2004;7(3):114-21.
22. Mekhjian HS, Philips SF, Hofman AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest. 1977;50:1569-77.
23. Newcomer AD. Surface digestion of carbohydrates. Mayo Clin Proc. 1973;48:620-3.
24. Bines J, Francis D, Hill D. Reducing parenteral requirement in children with short bowel syndrome: impact of an amino acidbased complete infant formula. J Pediatr Gastroenterol Nutr. 1998;26(2):123-8. (Pubitemid 28078472)
25. Vanderhoof JA, Young RJ. Hydrolyzed versus nonhydrolyzed protein diet in short bowel syndrome in children. J Pediatr Gastroenterol Nutr. 2004;38:107.
26. Parker P, Stroop S, Green H. A controlled comparison of continuous versus intermittent feedings in the treatment of infants with intestinal disease. J Pediatr. 1981;99:360-4. (Pubitemid 11029925)
27. Olieman JF, Penning C, Ijsselstijn H, et al. Enteral nutrition in children with short bowel syndrome: current evidence and recommendations for the clinician. J Am Diet Assoc. 2010;110:420-6.
28. Jaksik T, Shew SB, Keshen TH, et al. Do critically ill surgical neonates have increased energy expenditure? J Pediatr Surg. 2001;36(1):63-7. (Pubitemid 32044316)
29. Woolf GM, Miller C, Kurian R, et al. Nutrional absorption in short bowel syndrome. Evaluation of fluid, calorie, and divalent cation requirements. Dig Dis Sci. 1987;32(1):8-15. (Pubitemid 17227517)
30. Yang CJ, Duro D, Zurakowski D, et al. High prevalence of multiple micronutrient deficiencies in children with intestinal failure: a longitudinal study. J Pediatr. 2011;159:39-44.
31. Oversen L, Chu R, Howard L. The influence of dietary fat on jejunostomy output in patients with severe short bowel syndrome. Am J Clin Nutr. 1983;38(2):270-7. (Pubitemid 13044827)
32. Holleland G, Schneede J, Ueland PM, et al. Cobalamin deficiency in general practice. Assessment of the diagnostic utility and cost-benefit analysis of methylmalonic acid determination in relation to current diagnostic strategies. Clin Chem. 199;45(2):189-198.
33. Green R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. Am J Clin Nutr. 2011 Jul 6. [Epub ahead of print]PMID: 21733877.
34. Crenn P, et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology. 2000;119(6):1496-505. (Pubitemid 32198675)
35. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr. 2008;27(3):328-39.
36. Hull MA, Jones BA, Zurakowski D, Raphael B, Lo C, Jaksic T, Duggan C. Low serum citrulline concentration correlates with catheter-related bloodstream infections in children with intestinal failure. JPEN J Parenter Enter Nutr. 2011;35(2):181-7.
37. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60 (7):902-14.
38. Rager R, Finegold MJ. Cholestasis in immature newborn infants: is prenteral alimentation responsible? J Pediatr. 1975;86:264-89.
39. Kelly DA. Liver complications of pediatric prenteral nutrition - epidemiology. Nutrition. 1998;14:153-7. (Pubitemid 28049003)
40. Carter BA, Shulman RJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2007;4 (5):277-87. (Pubitemid 46711465)
41. Gunsar C, et al. The biochemical and histological effects of ursodeoxycholic acid and metronidazole on total parenteral nutritionassociated hepatic dysfunction: an experimental study. Hepatogastroenterology. 2002;49:497-500. (Pubitemid 34606581)
42. Lindor KD, Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis: a case report. Gastroenterology. 1991;101:250-3.
43. Tsai S, et al. Failure of cholecystokinin-octapeptideto prevent TPN-associated gallstone disease. J Pediatr Surg. 2005;40:263-7. (Pubitemid 40143569)
44. Heubi JE, et al. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr. 2002;141:237-42.
45. Cavicchi M, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132:525-32. (Pubitemid 30171891)
46. Colomb V, et al. Long-term parenteral nutrition in children: liver and gallbladder disease. Transplant Proc. 1992;24:1054-5.
47. Cober MP, Teitelbaum DH. Prevention of parenteral nutrition associated liver disease: lipid minimization. Curr Opin Organ Transplant. 2010;15:330-3.
48. Clayton PT, et al. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology. 1993;105:1806-13. (Pubitemid 24002799)
49. Carter BA, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor, FXR. Pediatr Res. 2007.
50. Gura KM, et al. Reversal of parenteral nutrition-associated liver disease in two infantswith short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006;118:e197-201. (Pubitemid 46071136)
51. de Meijer VE, et al. Fish oil lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enter Nutr. 2009;33:541-7.
52. Lee S, et al. Current clinical applications of omega-6 and omega-3 fatty acids. Nutr Clin Pract. 2006;21:323-41.
53. Soden JS, et al. Failure of resolution of portal fibrosis during omega-3 fatty acid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr. 2010;156(2):327-31.
54. Gura KM, et al. Safety and efficacy of a fish oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008;121:e678-86.
55. Spaeth G, et al. Fibre is an essential ingredient in enteral diets to limit bacterial translocation in rats. Eur J Surg. 1995;161:513-8.
56. Goulet O, Ruemmele F. Causes and management of intestinal failure in children. Gastroenterology. 2006;130 suppl 1:s16-28. (Pubitemid 43208856)
57. Ohishi A, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocoele. J Pediatr. 2010;156(4):679-81.
58. Kurkchubasche AG, et al. Catheter sepsis in short bowel syndrome. Arch Surg. 1992;127:21-4.
59. Wolf A, Pohlandt F. Bacterial infection: the main cause of acute cholestasis in newborn infants receiving short-term parenteral nutrition. J Pediatr Gastroenterol Nutr. 1989;8:297-303. (Pubitemid 19087949)
60. Lichtman SN, et al. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology. 1991;13:766-72.
61. Ghose R, et al. Endotoxin leads to rapid subcellular re-localization pf hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept. 2004;2:4.
62. Onland W, et al. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch Pediatr Adolesc Med. 2006;160:1049-53. (Pubitemid 44520635)
63. McHugh GJ, et al. Polyurethane central venous catheters, hydrochloric acid, and 70 % ethanol: a safety evaluation. Anaesth Intensive Care. 1997;25(4):350-3. (Pubitemid 27389194)
64. Mouw E, et al. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. J Pediatr Surg. 2008;43(6):1025-9. (Pubitemid 351814902)
65. Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebocontrolled, double-blind clinical trial. Ann Surg. 2005;242(5):655-61. (Pubitemid 41567120)
66. Goulet O, Dabbas-Tyan M, Talbotec C, Kapel N, Rosilio M, et al. Effect of recombinant human growth hormone on intestinal absorption and body composition in children with short bowel syndrome. J Parenter Enter Nutr. 2010;5(34):513-20.
67. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120(4):806-15. (Pubitemid 32193176)